414 related articles for article (PubMed ID: 17961073)
1. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
3. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
4. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
Tigli H; Yazici H; Dalay N
Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129
[TBL] [Abstract][Full Text] [Related]
5. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
dos Santos RM; de Jesus CM; Trindade Filho JC; Trindade JC; de Camargo JL; Rainho CA; Rogatto SR
DNA Cell Biol; 2008 Sep; 27(9):497-503. PubMed ID: 18491956
[TBL] [Abstract][Full Text] [Related]
6. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
[TBL] [Abstract][Full Text] [Related]
7. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
Zambra FM; Biolchi V; Brum IS; Chies JA
Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
[TBL] [Abstract][Full Text] [Related]
8. Association of G/A polymorphism, rs266882, in AREI region of the prostate-specific antigen gene with prostate cancer risk and clinicopathological features.
Samzadeh M; Hasanzad M; Jamaldini SH; Haghdoost AA; Afshari M; Ziaee SA
Urol J; 2012; 9(4):691-9. PubMed ID: 23235975
[TBL] [Abstract][Full Text] [Related]
9. Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
Binnie MC; Alexander FE; Heald C; Habib FK
Prostate; 2005 Jun; 63(4):309-15. PubMed ID: 15599941
[TBL] [Abstract][Full Text] [Related]
10. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population.
Soni A; Bansal A; Mishra AK; Batra J; Singh LC; Chakraborty A; Yadav DS; Mohanty NK; Saxena S
Genet Test Mol Biomarkers; 2012 Aug; 16(8):835-40. PubMed ID: 22731640
[TBL] [Abstract][Full Text] [Related]
11. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.
Antognelli C; Mearini L; Talesa VN; Giannantoni A; Mearini E
Prostate; 2005 May; 63(3):240-51. PubMed ID: 15538743
[TBL] [Abstract][Full Text] [Related]
12. A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Gsur A; Bernhofer G; Hinteregger S; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M
Int J Cancer; 2000 Aug; 87(3):434-7. PubMed ID: 10897051
[TBL] [Abstract][Full Text] [Related]
13. Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer.
Tajtakova M; Pidanicova A; Valansky L; Lachvac L; Nagy V; Sivonova M; Dobrota D; Kliment J; Petrovicova J
Neoplasma; 2010; 57(2):118-22. PubMed ID: 20099974
[TBL] [Abstract][Full Text] [Related]
14. Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population.
Sobti RC; Gupta L; Singh SK; Seth A; Kaur P; Thakur H
Cancer Genet Cytogenet; 2008 Sep; 185(2):78-85. PubMed ID: 18722876
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population.
Wang LZ; Sato K; Tsuchiya N; Yu JG; Ohyama C; Satoh S; Habuchi T; Ogawa O; Kato T
Cancer Lett; 2003 Dec; 202(1):53-9. PubMed ID: 14643026
[TBL] [Abstract][Full Text] [Related]
16. Association of benign prostate hyperplasia with polymorphisms in VDR, CYP17, and SRD5A2 genes among Lebanese men.
El Ezzi AA; Zaidan WR; El-Saidi MA; Al-Ahmadieh N; Mortenson JB; Kuddus RH
Asian Pac J Cancer Prev; 2014; 15(3):1255-62. PubMed ID: 24606449
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer associated with CYP17 genotype.
Wadelius M; Andersson AO; Johansson JE; Wadelius C; Rane E
Pharmacogenetics; 1999 Oct; 9(5):635-9. PubMed ID: 10591544
[TBL] [Abstract][Full Text] [Related]
18. Relationship between CYP17 gene polymorphisms and risk of prostate cancer.
Song J; Tao ZH; Liu XY; Gong S; Gan L
Genet Mol Res; 2016 Feb; 15(1):15017866. PubMed ID: 26985923
[TBL] [Abstract][Full Text] [Related]
19. Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
Das K; Cheah PY; Lim PL; Zain YB; Stephanie FC; Zhao Y; Cheng C; Lau W
Cancer Lett; 2008 Sep; 268(2):340-7. PubMed ID: 18495332
[TBL] [Abstract][Full Text] [Related]
20. CYP17 gene polymorphism and its association in north Indian prostate cancer patients.
Sobti RC; Gupta L; Thakur H; Seth A; Singh SK; Kaur P
Anticancer Res; 2009 May; 29(5):1659-63. PubMed ID: 19443382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
